| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0008100 | Intron-Intron | chr6:4894107-4920371 | chr6:4893873-4920137 | 447 nt | 0.4251 |
| hsa_CDYL_0008200 | Intron-Intron | chr6:4894107-4924979 | chr6:4893873-4924745 | 339 nt | 0.3982 |
| hsa_CDYL_0008300 | Intron-Intron | chr6:4894212-4896696 | chr6:4893978-4896462 | 2485 nt | 0.3980 |
| hsa_CDYL_0008400 | Intron-Intron | chr6:4894212-4906617 | chr6:4893978-4906383 | 140 nt | 0.3714 |
| hsa_CDYL_0008500 | Intron-Intron | chr6:4894212-4912679 | chr6:4893978-4912445 | 63 nt | 0.4762 |
| hsa_CDYL_0008600 | Intron-Intron | chr6:4898870-4899253 | chr6:4898636-4899019 | 384 nt | 0.4323 |
| hsa_chr6_0551000 | Intergenic-Intergenic | chr6:4900331-4900489 | chr6:4900097-4900255 | 159 nt | 0.3208 |
| hsa_chr6_0551100 | Intergenic-Intergenic | chr6:4904083-4905932 | chr6:4903849-4905698 | 1850 nt | 0.4838 |
| hsa_CDYL_0008700 | Intron-Intron | chr6:4906511-4912744 | chr6:4906277-4912510 | 250 nt | 0.3840 |
| hsa_CDYL_0008800 | Intron-Intron | chr6:4906511-4920371 | chr6:4906277-4920137 | 107 nt | 0.3925 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].